TS 172
Alternative Names: TS-172Latest Information Update: 18 Oct 2024
At a glance
- Originator Taisho Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hyperphosphataemia
Most Recent Events
- 26 Sep 2024 Taisho Pharmaceutical initiates enrollment in a phase I mass balance trial (In volunteers) in Japan(PO) (NCT06596356)
- 26 Sep 2024 Taisho Pharmaceutical plans a phase I trial (In volunteers) in an undisclosed location (PO) in September 2024 (NCT06596356)
- 26 Dec 2023 Taisho Pharmaceutical completes phase II clinical trial in Hyperphosphataemia (In adults, In the elderly) in Japan (PO) (NCT05699239)